Reneo Pharmaceuticals announces poster presentation on mavodelpar

Reneo Pharmaceuticals announced the company will present a poster titled “Selective peroxisome proliferator-activated receptor delta agonist, mavodelpar, improves cellular bioenergetics in fibroblasts from patients with mitochondrial complex I deficiency” at the following upcoming scientific meetings. PittGene Meeting; Date: Wednesday, October 25, 2023, at 2:00-2:45pm ET. Translational Research in Mitochondria, Metabolism, Aging and Disease Meeting 2023; Date: Monday, November 6, 2023, at 5:30-7:00pm ET. In this presentation, Reneo and collaborators will report findings which demonstrate that the bioenergetic deficiencies and mitochondrial dysfunction observed in CI-deficient patient fibroblasts can potentially be alleviated by treatment with mavodelpar, a potent and selective PPARdelta agonist. Furthermore, because mavodelpar activation results in increased transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation and energy production in the form of ATP, these results provide mechanistic evidence for the potential of mavodelpar as a therapeutic option in this and similar types of primary mitochondrial myopathies.